CDH1 and cancer: Our data suggest that entinostat, in contrast with other potential chemoprevention drugs [9,10], may be able to reduce cancer risk by both promoting apoptosis in established CDH1-null foci and preventing the initiation of new foci by maintaining the integrity of the epithelial plane.